INMB INmune Bio, Inc.: Forward P/S Multiple
INmune Bio, Inc. (INMB) specializes in developing immunotherapies to combat Alzheimer's disease. The forward P/S multiple confirms market expectations, where the 767.40 level captures the current valuation. A high reliance on external research centers is offset by strict internal oversight. Furthermore, drug development is not subject to economic cycles, demonstrating high resilience to macroeconomic fluctuations.
Metric breakdowns and analytics for INmune Bio Corporation (INMB)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
INMB - Company Net Income|Projected Future Earnings INmune Bio, Inc.|INMB - Business Payback Period|Future Price to Earnings INmune Bio Corp|INMB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio INmune Bio Corporation|INMB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) INmune Bio|INMB - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months inmunebio.com|INMB - Earnings per share growth this year|Earnings growth forecast for next year INmune Bio, Inc.
- sales and revenue indicators:
Fundamental company valuation:INmune Bio INMB
The forward P/S reflects the ratio of current market capitalization to projected revenue, allowing investors to track the dynamics of market sales expectations and separate the fundamental trend from volatility. By analyzing this forward price-to-sales chart, one can assess the risk of overpaying for the innovations of INmune Bio, Inc. (INMB) in the field of Alzheimer's disease therapy, where the asset's high valuation is justified by the potential of breakthrough immunological developments.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio ADMA Corp ADMA|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue IMVT|Price-to-Projected Revenue Ratio Kiniksa|Forward Price-to-Revenue Multiple Grifols SA (GRFS)|Forward Price-to-Revenue Multiple ADPT (Adaptive Biotechnologies Corp)|Forward P/S Multiple Celldex Corp (CLDX)|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|BCRX: Market Cap to Projected Revenue|Vera Therapeutics - Forward P/S Multiple|Market Cap to Future Revenue Ratio Dianthus Therapeutics Inc|PHVS (Pharvaris Corp) - Forward Price-to-Revenue Multiple|AbCellera Corp - Forward Price to Sales|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio PGEN|Forward P/S Multiple PHAR|Market Cap to Expected Sales Ratio Nektar Therapeutics Inc|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|Zenas Corp (ZBIO) - Market Cap to Future Revenue Ratio|IMNM: Forward Price-to-Revenue Multiple|Forward Price to Sales GOSS (gossamerbio.com)|KALV: Forward P/S Multiple|SEPN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|Market Cap to Projected Revenue SVRA (Savara Pharma)|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple anaptysbio.com ANAB|Astria Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio enGene Holdings Inc (ENGN)|RAPT Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Aerovate Therapeutics Inc JBIO|Aclaris Therapeutics (ACRS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue KYTX|Price-to-Projected Revenue Ratio Tiziana Life Sciences Ltd|Forward Price-to-Revenue Multiple Cabaletta Bio Inc. (CABA)|Forward P/S Multiple VTYX|Price-to-Projected Revenue Ratio THTX (Theratechnologies, Inc)|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|ELDN (eledon.com) - Future Price to Revenue|Agenus Inc. - Forward P/S Multiple|Forward Price to Sales CLYM (Climb Bio Inc.)|ZURA: Forward P/S Multiple|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Adagene Inc|IMA: Forward Price to Sales|Price-to-Projected Revenue Ratio Shattuck Labs, Inc. (STTK)|Forward Price-to-Revenue Multiple equilliumbio.com EQ|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|Forward P/S Multiple Immunic Therapeutics IMUX|ATRA: Forward Price-to-Revenue Multiple|Forward Price to Sales IFRX (InflaRx N.V.)|XFOR: Forward P/S Multiple|ACET - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Celularity Inc|Forward Price-to-Revenue Multiple Barinthus Biotherapeutics Corp (BRNS)|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|Forward Price-to-Revenue Multiple sabbiotherapeutics.com SABS|Akari Therapeutics Plc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Enlivex Therapeutics Ltd ENLV|QTTB - Price-to-Projected Revenue Ratio|GOVX (GeoVax Corp) - Market Cap to Projected Revenue|EDSA: Forward P/S Multiple|Market Cap to Future Revenue Ratio ibioinc.com (IBIO)|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|hcwbiologics.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM - Forward Price-to-Revenue Multiple|ADTX: Forward Price-to-Revenue Multiple|GRI - Forward P/S Multiple|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue HIND|REVB (Revelation Biosciences) - Forward P/S Multiple|Market Cap to Future Revenue Ratio indaptusrx.com INDP|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|CALI (calcimedica.com) - Forward Price to Sales|Forward P/S Multiple AFMD (Affimed N.V.)|Allakos Inc - Price-to-Projected Revenue Ratio|HOOKIPA - Forward P/S Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Ocean Biomedical Inc (OCEA)|Forward Price-to-Revenue Multiple TCBP|THRD: Forward Price to Sales
